DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages

Angioimmunoblastic T-cell lymphoma

Authors: Dr Flora Poon, Victorian Dermatology Registrar, St. Vincent’s Hospital, Melbourne, VIC, Australia; Dr Christopher Y Chew, Medical Resident, Monash Health, Melbourne, VIC, Australia; Dr Rubeta N Matin, Consultant Dermatologist, Oxford University Hospitals, Oxford, UK. DermNet NZ Editor in Chief: Adjunct A/Prof. Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. March 2020.


What is angioimmunoblastic T-cell lymphoma?

Angioimmunoblastic T-cell lymphoma is a rare nodal peripheral T-cell lymphoma (PTCL) that results in systemic symptoms and profound immune deficiency [1]. It sometimes causes a rash.

Angioimmunoblastic T-cell lymphoma is characterised histologically by a polymorphous infiltrate primarily involving lymph nodes, a proliferation of high endothelial venules, and follicular dendritic cells [2].

Who gets angioimmunoblastic T-cell lymphoma?

Angioimmunoblastic T-cell lymphoma is rare.

  • Peripheral T-cell lymphomas comprise 10–15% of all lymphoid malignancies [1,3]
  • Angioimmunoblastic T-cell lymphoma accounts for 15–20% of peripheral T-cell lymphomas and 1–2% of non-Hodgkin lymphomas [4].

Typically, angioimmunoblastic T-cell lymphoma affects older adults [4]. The median age of diagnosis is 62–65 years. Incidence is equal in men and women [4].

No risk factors have been identified for angioimmunoblastic T-cell lymphoma.

What causes angioimmunoblastic T-cell lymphoma?

The cell of origin of angioimmunoblastic T-cell lymphoma is the follicular helper T-cell [4]. Malignant transformation has been associated with mutations in the epigenetic regulators (TET2, IDH2 and DNMT3A), the Ras homolog gene family member A (RHOA) and T-cell receptor pathway (CD28, FYN, PLCG1, CARD11, P13K elements, CTNNB1, and GTF2I) [4].

Angioimmunoblastic T-cell lymphoma is promoted by the overexpression of angiogenic mediators (factors that regulate the development of blood vessels), such as vascular endothelial growth factor (VEGF) and interleukin (IL)-8, and cytokines that are proinflammatory (IL6, IL18), immunosuppressive (IL10), or induce proliferation (IL21) [4,5].

Infectious diseases associated with angioimmunoblastic T-cell lymphoma include Epstein-Barr virus (EBV, the cause of infectious mononucleosis), human herpesvirus 6 (HHV6) (the cause of roseola), HHV 8 (the cause of Kaposi sarcoma), human immunodeficiency virus (HIV), bacterial infections and fungal infections [4].

The role of Epstein Barr virus

EBV establishes lifelong persistent infection in B cells. The immunodeficiency caused by angioimmunoblastic T-cell lymphoma reactivates EBV [4,6–8].

  • EBV-infected B cells are present in 58–97% of patients with angioimmunoblastic T-cell lymphoma [8,9].
  • EBV (and potentially HHV 6) may play a role in promoting disease progression through modulation of cytokines, chemokines, and membrane receptors [6].
  • EBV is thought to prolong the life span of the B-cell and may cause genetic aberrations, such as preventing c-myc-induced apoptosis, leading to B-cell lymphoma [4,8,10]. See Epstein–Barr virus-associated lymphoproliferative disorders.

What are the clinical features of angioimmunoblastic T-cell lymphoma?

More than 70% of patients with angioimmunoblastic T-cell lymphoma present with constitutional symptoms. These include fevers, chills, night sweats, malaise, weight loss, arthralgias, and in 50%, a rash [11].

Lymphadenopathy and hepatosplenomegaly are typically present on examination. Pleural effusions, ascites, neurological signs, and gastrointestinal symptoms are less common [4].

Cutaneous features of angioimmunoblastic T-cell lymphoma

Angioimmunoblastic T-cell lymphoma most often presents with a non-specific rash [11]. It can also result in papules, nodules, plaques, ulcers, petechiae, and, rarely, erythroderma [8,11,12].

Rash associated with angioimmunoblastic T-cell lymphoma

What are the complications of angioimmunoblastic T-cell lymphoma?

Patients with angioimmunoblastic T-cell lymphoma are at increased risk of a secondary B-cell lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), and less commonly, Hodgkin lymphoma, or plasmacytoma [13].

There are 30 documented cases of EBV-associated B-cell lymphomas in patients with angioimmunoblastic T-cell lymphoma (November 2019) [14–16].

EBV-induced diffuse large B-cell lymphoma can also present with cutaneous signs, including ulcerated papules, nodules, and abscesses [16].

How is angioimmunoblastic T-cell lymphoma diagnosed?

Laboratory abnormalities include:

  • Anaemia (often haemolytic, with a positive Coombs test)
  • Eosinophilia
  • Polyclonal hypergammaglobulinaemia
  • Antinuclear antibodies (ANA)
  • Cold agglutinins
  • Cryoglobulinaemia
  • Circulating immune complexes
  • Elevated serum lactate dehydrogenase (LDH) and beta-2-microglobulin
  • Elevated EBV.

Peripheral blood leukocytosis with lymphocytosis is uncommon. Flow cytometry can be used to detect aberrant T-cells [17].

The diagnosis of angioimmunoblastic T-cell lymphoma is typically established by lymph node biopsy.

There are five angioimmunoblastic T-cell lymphoma histopathological patterns in the skin.

  • A superficial perivascular infiltrate composed of eosinophils and lymphocytes that lack atypia (the most common pattern)
  • A sparse perivascular infiltrate with atypical lymphocytes
  • A dense superficial and deep infiltrate of pleomorphic lymphocytes
  • Vasculitis, with or without atypical lymphocytes
  • Necrotising granulomas.

Histology of angioimmunoblastic T-cell lymphoma

The immunophenotype of neoplastic cells typically corresponds to follicular T-helper cells (CD3+, CD4+, CD8−, CD10+, PD-1+, ICOS+, Bcl-6+, chemokine ligand CXCL13+) plus clusters of CD21+ follicular dendritic cells.

EBV positivity found on an immunohistochemistry stain is reportedly higher in more mature lesions and occasionally forms diffuse patterns [18].

Immunohistochemistry of angioimmunoblastic T-cell lymphoma

What is the differential diagnosis for cutaneous angioimmunoblastic T-cell lymphoma?

The differential diagnosis of cutaneous angioimmunoblastic T-cell lymphoma depends on the morphology of the cutaneous rash, but can include:

What is the treatment for angioimmunoblastic T-cell lymphoma?

Due to the rarity of angioimmunoblastic T-cell lymphoma, therapy is generally guided by prospective phase II studies [4].

  • The most common treatment is anthracycline-based chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone).
  • Follow-up consolidation with autologous stem-cell transplantation has shown promising results [19].
  • Trials of histone deacetylase (HDAC) inhibitors, hypomethylating agents, and anti-CD30 antibodies are on-going [20–23].

What is the outcome for angioimmunoblastic T-cell lymphoma?

Angioimmunoblastic T-cell lymphoma is typically aggressive with a median survival of fewer than 3 years, even with intensive treatment.

  • Standard CHOP chemotherapy has an overall response rate of 70–80% and 5-year progression-free survival of 10–20% [8,24].
  • Follow-up BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous stem-cell transplantation have a 5-year progression-free survival rate of around 40% [25].

Circulating EBV DNA levels may be monitored; higher levels are associated with poorer prognosis. However, the presence of EBV in nodal tumours does not alter prognosis.

Secondary B-cell lymphomas have a typically poor prognosis. Eight out of 30 patients with EBV-associated B-cell lymphoma survived beyond 12 months [14–16].

See smartphone apps to check your skin.
[Sponsored content]

 

Related information

 

References

  1. Swerdlow S, Campo E, Pileri S, et al. The 2016 revision of the World Health Organisation classification of lymphoid neoplasms. Blood 2016; 127: 2375–90. DOI: 10.1182/blood-2016-01-643569. PubMed
  2. Carbone A, Gloghini A, Dotti G. EBV-Associated Lymphoproliferative Disorders: Classification and Treatment. Oncologist 2008; 13: 577–85. DOI: 10.1634/theoncologist.2008-0036. PubMed
  3. Jaffe ES, Ralfkiaer E. Mature T-cell and NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, et al (eds). World Health Organisation Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001. 189–235.
  4. Yabe M, Dogan A, Horwitz S, Moskowitz A. Angioimmunoblastic T-Cell Lymphoma. Cancer Treat Res 2018: 99–126. DOI: 10.1007/978-3-319-99716-2_5. PubMed
  5. Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123: 2915–23. DOI: 10.1182/blood-2013-11-536359. PubMed Central
  6. Bräuninger A, Spieker T, Willenbrock K, et al. Survival and clonal expansion of mutating “forbidden” (immunoglobulin receptor–deficient) Epstein-Barr virus–infected B cells in angioimmunoblastic T cell lymphoma. J Exp Med 2001; 194: 927–940. DOI: 10.1084/jem.194.7.927. PubMed
  7. Zhou Y, Attygalle A, Chuang S, et al. Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 2007; 138: 44–53. DOI: 10.1111/j.1365-2141.2007.06620.x. PubMed
  8. Dogan A, Gaulard P, Jaffe ES, et al. Angioimmunoblastic T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al (eds). WHO classification of tumours of heamatotopoetic and lymphoid tissues. 4th edition. Lyon, France: IARC Press; 2008: 309–11.
  9. Attygalle A, Chuang S, Diss T, Du M, Isaacson P, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology 2007; 50: 498–508. DOI: 10.1111/j.1365-2559.2007.02632.x. PubMed
  10. Allday M. How does Epstein–Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Semin Cancer Biol 2009; 19: 366–376. DOI: 10.1016/j.semcancer.2009.07.007. PubMed
  11. De Leval L, Gisselbrecht C, Galard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematology 2010; 148: 673–89. DOI: 10.1111/j.1365-2141.2009.08003.x. PubMed
  12. Martel P, Laroche L, Courville P, et al. Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological and molecular analysis. Arch Dermatol. 2000; 136: 881–886. DOI:10.1001/archderm.136.7.881. PubMed
  13. Willenbrock K, Bräuninger A, Hansmann M. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 2007; 138(6): 733–739. DOI: 10.1111/j.1365-2141.2007.06725.x. PubMed
  14. Şimşek C, Bostankolu B, Özoğul E, Sağlam Ayhan A, Üner A, Büyükaşık Y. EBV-Related Diffuse Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. Turk J Haematol 2019; 36: 57–9. DOI: 10.4274/tjh.2018.0023. PubMed Central
  15. Szablewski V, Dereure O, René C, et al. Cutaneous localisation of angioimmunoblastic T‐cell lymphoma may masquerade as B‐cell lymphoma or classical Hodgkin lymphoma: A histologic diagnostic pitfall. J Cutan Pathol 2019; 46: 102–10. DOI:10.1111/cup.13382. PubMed
  16. Poon F, Ieremia E, Collins G, Matin RN. Epstein-Barr Virus-Induced Cutaneous Large B-Cell Lymphoma in a Patient With Angioimmunoblastic T-Cell Lymphoma. Am J Dermatopathol 2019; 41: 927-30. DOI: 10.1097/DAD.0000000000001371. PubMed
  17. Singh A, Schabath R, Ratei R, et al. Peripheral blood sCD3−CD4+T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol 2013; 32: 16–21. DOI: 10.1002/hon.2080. PubMed
  18. Bolognia J, Schaffer J, Cerroni L. Dermatology [2 volumes]. 4th ed. London: Elsevier; 2018. 2158.
  19. d'Amore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H et al. Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093–99. DOI: 10.1200/JCO.2011.40.2719. PubMed
  20. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Feb 29, 2000. Identifier NCT01796002, Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma; 2013 February 13 [cited Oct 06, 2019]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01796002
  21. Horwitz S, O'Connor O, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019; 393: 229–40. DOI: 10.1016/S0140-6736(18)32984-2. PubMed
  22. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Feb 29, 2000. Identifier NCT03161223, Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma; 2017 May 19 [cited Oct 06, 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03161223
  23. O'Connor O, Falchi L, Lue J, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase I study. Blood 2019; 134: 1395–1405. DOI: 10.1182/blood.2019001285. PubMed
  24. Savage K, Chhanabhai M, Gascoyne R, Connors J. Characterisation of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467–75. DOI: 10.1093/annonc/mdh392. PubMed
  25. Mehta N, Maragulia J, Moskowitz A, et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk 2013; 13: 664–70. DOI: 10.1016/j.clml.2013.07.005. PubMed

DermNet NZ

Other websites

Books about skin diseases